Invention:
This innovation relates to analogs/mimetics of CC16 also known as Urinary protein 1 (UPI), or Clara cell protein, or club cell protein. This protein is targeted for the treatment of cancer, chronic obstructive pulmonary disease, asthma, cystic fibrosis and any other diseases that CC16 may have activity in. The inventors have discovered a novel site of activity that binds to an antigen on activated immune cells and an antigen on airway epithelial cells. Researchers found that when delivered into the bloodstream, CC16 rescues lung function, limits immune cell migration into the lungs, and enhances epithelial host responses to pathogens, ultimately playing a dual role as an anti-inflammatory protein in circulation and promoting secretion of defensive factors to aid in pathogen clearance. Further research with these CC16-derived peptidomimetics will work to develop a lead compound for enhanced solubility, efficacy, and stability while minimizing size and toxicity.
Background:
Chronic obstructive pulmonary disease, or COPD, covers a large group of lung diseases including emphysema and chronic bronchitis. This disease is characterized by recurrent respiratory infections and the occurrence of systemic and airway inflammation. COPD is now the third leading cause of death worldwide and while there are limited treatment options such as life-long supplemental oxygen and lung transplants, there is no known cure for COPD.
Applications:
- Treatment for chronic obstructive pulmonary disease, asthma, and other respiratory diseases
- Therapeutic treatment for cancer, cystic fibrosis, ARDS, and other diseases that CC16 has activity in
Advantages:
- Reduces inflammation
- Rescues lung function
- Enhances defensive response to pathogens
- Potential for various indications
